Metagenomi Therapeutics (MGX) Non-cash Items (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Non-cash Items data on file, last reported at $1.3 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $1.3 million, up 426.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 426.58% YoY), and the FY2025 annual result was $265000.0, up 63.23% from the prior year.
• Non-cash Items climbed to $1.3 million in Q1 2026 per MGX's latest filing, from $265000.0 in the prior quarter.
• Over five years, Non-cash Items peaked at $111.0 million in Q4 2023 and troughed at $3246.0 in Q2 2024.
• A 4-year average of $12.8 million and a median of $715000.0 in 2024 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2024 and 2025: Non-cash Items tumbled 99.36% in 2024, then surged 27335.4% in 2025.
• A 4-year view of Non-cash Items shows it stood at $111.0 million in 2023, then plunged by 99.36% to $715000.0 in 2024, then sank by 62.94% to $265000.0 in 2025, then jumped by 373.95% to $1.3 million in 2026.
• Business Quant data shows MGX's Non-cash Items at $1.3 million in Q1 2026, $265000.0 in Q4 2025, and $1.1 million in Q3 2025.